Breast Cancer

18 competing products in clinical development for Breast Cancer.

Pipeline by Phase

Pre-clinical1

Phase 13

Phase 1/22

Phase 28

Phase 33

Approved1

All Products (18)

Product	Company	Stage	Status	Hype
arzoxifene	Eli Lilly	Approved	Completed	85
gemcitabine hydrochloride + paclitaxel	Eli Lilly	Phase 3	Completed	77
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	Completed	69
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	Completed	69
gemcitabine + paclitaxel + bevacizumab	Eli Lilly	Phase 2	Completed	52
Gemcitabine + Adriamycine + Paclitaxel	Eli Lilly	Phase 2	Completed	52
gemcitabine + vinorelbine	Eli Lilly	Phase 2	Completed	52
pemetrexed + cyclophosphamide + doxorubicin + docetaxel	Eli Lilly	Phase 2	Completed	52
pemetrexed + gemcitabine	Eli Lilly	Phase 2	Completed	52
Experimental Arm A: Pemetrexed + Experimental Arm A: Sorafenib + Experimental Arm B: Pemetrexed + Experimental Arm B: Sorafenib	Eli Lilly	Phase 2	Terminated	52
pemetrexed	Eli Lilly	Phase 2	Completed	52
Alpelisib + Tamoxifen + Zotatifin + Fulvestrant	eFFECTOR Therapeutics	Phase 2	Completed	44
VS-6766 + Abemaciclib + Fulvestrant	Eli Lilly	Phase 1/2	Recruiting	41
Azenosertib + Carboplatin + Pembrolizumab	Zentalis Pharmaceuticals	Phase 1/2	Active	33
BBI-940 + Fulvestrant	Boundless Bio	Phase 1	Recruiting	25
tomivosertib + paclitaxel	eFFECTOR Therapeutics	Phase 1	Completed	25
Pelareorep + Letrozole + Atezolizumab + Trastuzumab	Biotech Research Group	Phase 1	Terminated	25
Biomarkers blood, urine and microbiota samples	Eli Lilly	Pre-clinical	Active	23